ARDX · ARDELYX, INC.
← all insidersPharmaceutical Preparations · Listed on Nasdaq
Open-market insider flow over 30d · 90d · 180d · 365d · filter in table · CSV · JSON
Open-market trades24
Distinct insiders8
Bought$0
Sold$1.42M
Net flow$-1.42M
Recent filings
How to read this
- Filed
- Date the Form 4 was filed with the SEC. Insiders must file within 2 business days of the trade.
- Ticker
- The issuer's stock symbol. Select it to open that company's insider-activity page.
- Issuer
- The company whose shares were traded.
- Sector
- The issuer's industry (SEC SIC classification). Select a value to filter to that sector.
- Insider
- The reporting person: an officer, director, or 10% owner. Select a name to see all of their trades.
- Role
- The insider's relationship to the company: director, officer, or 10% owner.
- Code
- SEC transaction code describing the kind of transaction. Full official definitions are under “Transaction codes” below. A dot marks an open-market trade (P/S), the highest-conviction signal.
- Side
- Direction of the trade, from the filing's Acquired (A) ▲ / Disposed of (D) ▼ field: a buy or a sell.
- 10b5-1
- Trade made under a pre-arranged Rule 10b5-1 plan: scheduled in advance, not a discretionary decision (generally lower signal).
- Shares
- Number of shares in this transaction.
- Price
- Reported price per share. Blank for grants, gifts, and other trades with no stated price.
- Value
- Transaction value = shares × price. Left blank for grants, option exercises, gifts, and conversions, which have no cash price (see Own Δ for their impact).
- Owned after
- Form 4 column “Amount of Securities Beneficially Owned Following Reported Transaction(s)”: shares the insider held (directly or indirectly) immediately after this trade.
- Own Δ
- How much this trade changed the insider's own holding versus what they held just before it (not a share of the company). +45% grew it by 45%, 2.0× more than doubled it, −100% sold the entire stake, “new” built a position from nothing.
- Co. Δ
- Change in the insider's stake as a share of the whole company from this trade (transaction shares ÷ shares outstanding). The “(now …)” figure is their resulting total stake. Based on the latest reported shares outstanding; blank when unavailable.
- D/I
- Form 4 column “Ownership Form: Direct (D) or Indirect (I)”. Indirect holdings (for example, through a trust, fund, or family member) are detailed in the filing's “Nature of Indirect Beneficial Ownership.”
- Lag
- Days from the trade date to the filing date (Form 4 is due within 2 business days).
Transaction codes
Verbatim from the SEC's General Instructions for Forms 3, 4 and 5.
- P
- Open market or private purchase of non-derivative or derivative security
- S
- Open market or private sale of non-derivative or derivative security
- A
- Grant, award or other acquisition pursuant to Rule 16b-3(d)
- D
- Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
- F
- Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
- M
- Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
- G
- Bona fide gift
- C
- Conversion of derivative security
- X
- Exercise of in-the-money or at-the-money derivative security
- J
- Other acquisition or disposition (describe transaction)
| Filed ↓Date the Form 4 was filed with the SEC (due within 2 business days of the trade). | Insider | Role | CodeSEC transaction code describing the kind of transaction. See “How to read this” above for the official SEC definition of each code. The dot marks an open-market trade (P/S). | SideDirection of the trade: a buy (acquired ▲) or a sell (disposed ▼). | Shares | PriceReported price per share. Blank for trades with no stated price. | ValueTransaction value = shares × price. Left blank for grants, option exercises, gifts, and conversions, which have no cash price (see Own Δ). | Owned afterShares the insider held (directly or indirectly) immediately after this trade. | Own ΔHow much this trade changed the insider's own holding versus what they held just before it (not a share of the company). +45% grew it by 45%, 2.0× more than doubled it, −100% sold the entire stake, “new” built a position from nothing. | Co. ΔChange in the insider's stake as a share of the whole company from this trade (transaction shares ÷ shares outstanding). The “(now …)” figure is their resulting total stake in the company. Based on the latest reported shares outstanding; blank when unavailable. | Link to SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-25 | Hohenleitner Susan | Officer (Chief Financial Officer) | S | ▼ sell | 1,5580 | $3.86 | $6.0K | 227,520 | −0.7% | −<0.01% (now 0.09%) | filing |
| 2026-08-25 | Reilly Joseph James | Officer (See Remarks) | S | ▼ sell | 1,1100 | $3.86 | $4.3K | 145,854 | −0.8% | −<0.01% (now 0.06%) | filing |
| 2026-08-25 | Reilly Joseph James | Officer (See Remarks) | S | ▼ sell | 2,8720 | $3.86 | $11.1K | 146,964 | −2% | −<0.01% (now 0.06%) | filing |
| 2026-08-25 | Bishop John E | Officer (See Remarks) | S | ▼ sell | 2,4690 | $3.86 | $9.5K | 317,095 | −0.8% | −<0.01% (now 0.13%) | filing |
| 2026-08-25 | Bishop John E | Officer (See Remarks) | S | ▼ sell | 17,2810 | $3.86 | $66.7K | 319,564 | −5% | −<0.01% (now 0.13%) | filing |
| 2026-08-25 | Brady James Parker | Officer (Chief Human Resources Officer) | S | ▼ sell | 13,1600 | $3.86 | $50.8K | 245,930 | −5% | −<0.01% (now 0.10%) | filing |
| 2026-08-25 | Brady James Parker | Officer (Chief Human Resources Officer) | S | ▼ sell | 1,9760 | $3.86 | $7.6K | 259,090 | −0.8% | −<0.01% (now 0.10%) | filing |
| 2026-08-25 | Foster Eric Duane | Officer (Chief Commercial Officer) | S | ▼ sell | 2,5750 | $3.86 | $9.9K | 409,410 | −0.6% | −<0.01% (now 0.16%) | filing |
| 2026-08-25 | Foster Eric Duane | Officer (Chief Commercial Officer) | S | ▼ sell | 3,3890 | $3.86 | $13.1K | 411,985 | −0.8% | −<0.01% (now 0.17%) | filing |
| 2026-08-25 | Foster Eric Duane | Officer (Chief Commercial Officer) | S | ▼ sell | 2,5980 | $3.86 | $10.0K | 415,374 | −0.6% | −<0.01% (now 0.17%) | filing |
| 2026-08-25 | Kelliher Mike | Officer (Chief Business Officer) | S | ▼ sell | 2,0020 | $3.86 | $7.7K | 349,660 | −0.6% | −<0.01% (now 0.14%) | filing |
| 2026-08-25 | Kelliher Mike | Officer (Chief Business Officer) | S | ▼ sell | 2,6520 | $3.86 | $10.2K | 351,662 | −0.7% | −<0.01% (now 0.14%) | filing |
| 2026-08-25 | Kelliher Mike | Officer (Chief Business Officer) | S | ▼ sell | 3,1040 | $3.86 | $12.0K | 354,314 | −0.9% | −<0.01% (now 0.14%) | filing |
| 2026-08-25 | Williams Laura A | Officer (Chief Patient Officer) | S | ▼ sell | 1,7340 | $3.86 | $6.7K | 367,456 | −0.5% | −<0.01% (now 0.15%) | filing |
| 2026-08-25 | Williams Laura A | Officer (Chief Patient Officer) | S | ▼ sell | 2,4300 | $3.86 | $9.4K | 369,190 | −0.7% | −<0.01% (now 0.15%) | filing |
| 2026-08-25 | Williams Laura A | Officer (Chief Patient Officer) | S | ▼ sell | 3,0890 | $3.86 | $11.9K | 371,620 | −0.8% | −<0.01% (now 0.15%) | filing |
| 2026-08-25 | Williams Laura A | Officer (Chief Patient Officer) | S | ▼ sell | 3,4860 | $3.86 | $13.4K | 374,709 | −0.9% | −<0.01% (now 0.15%) | filing |
| 2026-08-25 | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell | 19,1780 | $3.86 | $74.0K | 1,619,792 | −1% | −<0.01% (now 0.65%) | filing |
| 2026-08-25 | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell | 8,4110 | $3.86 | $32.4K | 1,638,970 | −0.5% | −<0.01% (now 0.66%) | filing |
| 2026-08-25 | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell | 15,9760 | $3.86 | $61.6K | 1,647,381 | −1.0% | −<0.01% (now 0.66%) | filing |
| 2026-08-25 | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell | 15,0090 | $3.86 | $57.9K | 1,663,357 | −0.9% | −<0.01% (now 0.67%) | filing |
| 2026-07-17 | RAAB MICHAEL | Director, Officer (President & CEO) | M | ▼ sell10b5-1 | 20,834→ 20,834 Common Stock | — | — | 290,834 | — | — | filing |
| 2026-07-17 | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell10b5-1 | 41,6680 | $5.06 | $210.9K | 1,678,366 | −2% | −0.02% (now 0.67%) | filing |
| 2026-07-17 | RAAB MICHAEL | Director, Officer (President & CEO) | M | ▲ buy10b5-1 | 20,8340 | $0.99 | $20.6K | 1,720,034 | +1% | +<0.01% (now 0.69%) | filing |
| 2026-06-22 | Williams Laura A | Officer (Chief Patient Officer) | M | ▼ sell10b5-1 | 31,000→ 31,000 Common Stock | — | — | 31,000 | — | — | filing |
| 2026-06-22 | Williams Laura A | Officer (Chief Patient Officer) | S | ▼ sell10b5-1 | 81,8980 | $5.99 | $490.5K | 378,195 | −18% | −0.03% (now 0.15%) | filing |
| 2026-06-22 | Williams Laura A | Officer (Chief Patient Officer) | M | ▲ buy10b5-1 | 31,0000 | $0.99 | $30.7K | 460,093 | +7% | +0.01% (now 0.18%) | filing |
| 2026-06-18 | Bhanji Muna | Director | A | ▲ buy | 39,715→ 39,715 Common Stock | — | — | 39,715 | — | — | filing |
| 2026-06-18 | Bhanji Muna | Director | A | ▲ buy | 26,4550 | — | — | 163,808 | +19% | +0.01% (now 0.07%) | filing |
| 2026-06-18 | Cadoret-Manier Onaiza | Director | A | ▲ buy | 39,715→ 39,715 Common Stock | — | — | 39,715 | — | — | filing |
| 2026-06-18 | Cadoret-Manier Onaiza | Director | A | ▲ buy | 26,4550 | — | — | 178,156 | +17% | +0.01% (now 0.07%) | filing |
| 2026-06-18 | Parsey Merdad | Director | A | ▲ buy | 39,715→ 39,715 Common Stock | — | — | 39,715 | — | — | filing |
| 2026-06-18 | Parsey Merdad | Director | A | ▲ buy | 26,4550 | — | — | 83,746 | +46% | +0.01% (now 0.03%) | filing |
| 2026-06-18 | Bazemore Robert B | Director | A | ▲ buy | 39,715→ 39,715 Common Stock | — | — | 39,715 | — | — | filing |
| 2026-06-18 | Bazemore Robert B | Director | A | ▲ buy | 26,4550 | — | — | 68,006 | +64% | +0.01% (now 0.03%) | filing |
| 2026-06-18 | Rodgers Richard J | Director | A | ▲ buy | 39,715→ 39,715 Common Stock | — | — | 39,715 | — | — | filing |
| 2026-06-18 | Rodgers Richard J | Director | A | ▲ buy | 26,4550 | — | — | 439,998 | +6% | +0.01% (now 0.18%) | filing |
| 2026-06-18 | Bertrand William C JR | Director | A | ▲ buy | 39,715→ 39,715 Common Stock | — | — | 39,715 | — | — | filing |
| 2026-06-18 | Bertrand William C JR | Director | A | ▲ buy | 26,4550 | — | — | 329,507 | +9% | +0.01% (now 0.13%) | filing |
| 2026-06-18 | Bertrand William C JR | Director | A | ▲ buy | 12,3450 | — | — | 303,052 | +4% | +<0.01% (now 0.12%) | filing |
| 2026-06-18 | MOTT DAVID M | Director | A | ▲ buy | 39,715→ 39,715 Common Stock | — | — | 39,715 | — | — | filing |
| 2026-06-18 | MOTT DAVID M | Director | A | ▲ buy | 26,4550 | — | — | 3,349,655 | +0.8% | +0.01% (now 1.3%) | filing |
| 2026-06-18 | MOTT DAVID M | Director | A | ▲ buy | 20,2820 | — | — | 3,323,200 | +0.6% | +<0.01% (now 1.3%) | filing |
| 2026-06-17 | RAAB MICHAEL | Director, Officer (President & CEO) | M | ▼ sell10b5-1 | 20,833→ 20,833 Common Stock | — | — | 311,668 | — | — | filing |
| 2026-06-17 | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell10b5-1 | 41,6660 | $5.67 | $236.3K | 1,699,200 | −2% | −0.02% (now 0.68%) | filing |
| 2026-06-17 | RAAB MICHAEL | Director, Officer (President & CEO) | M | ▲ buy10b5-1 | 20,8330 | $0.99 | $20.6K | 1,740,866 | +1% | +<0.01% (now 0.70%) | filing |
| 2026-05-22 | Hohenleitner Susan | Officer (Chief Financial Officer) | S | ▼ sell | 1,4550 | $6.27 | $9.1K | 229,078 | −0.6% | −<0.01% (now 0.09%) | filing |
| 2026-05-22 | Brady James Parker | Officer (Chief Human Resources Officer) | S | ▼ sell | 1,8460 | $6.27 | $11.6K | 261,066 | −0.7% | −<0.01% (now 0.10%) | filing |
| 2026-05-22 | Reilly Joseph James | Officer (See Remarks) | S | ▼ sell | 1,0360 | $6.27 | $6.5K | 149,836 | −0.7% | −<0.01% (now 0.06%) | filing |
| 2026-05-22 | Reilly Joseph James | Officer (See Remarks) | S | ▼ sell | 2,6830 | $6.27 | $16.8K | 149,107 | −2% | −<0.01% (now 0.06%) | filing |
| 2026-05-22 | Foster Eric Duane | Officer (Chief Commercial Officer) | S | ▼ sell | 2,4050 | $6.27 | $15.1K | 417,972 | −0.6% | −<0.01% (now 0.17%) | filing |
| 2026-05-22 | Foster Eric Duane | Officer (Chief Commercial Officer) | S | ▼ sell | 2,4270 | $6.27 | $15.2K | 420,377 | −0.6% | −<0.01% (now 0.17%) | filing |
| 2026-05-22 | Foster Eric Duane | Officer (Chief Commercial Officer) | S | ▼ sell | 3,1660 | $6.27 | $19.8K | 422,804 | −0.7% | −<0.01% (now 0.17%) | filing |
| 2026-05-22 | Kelliher Mike | Officer (Chief Business Officer) | S | ▼ sell | 2,4780 | $6.27 | $15.5K | 357,418 | −0.7% | −<0.01% (now 0.14%) | filing |
| 2026-05-22 | Kelliher Mike | Officer (Chief Business Officer) | S | ▼ sell | 1,8700 | $6.27 | $11.7K | 359,896 | −0.5% | −<0.01% (now 0.14%) | filing |
| 2026-05-22 | Kelliher Mike | Officer (Chief Business Officer) | S | ▼ sell | 2,9000 | $6.27 | $18.2K | 361,766 | −0.8% | −<0.01% (now 0.15%) | filing |
| 2026-05-22 | Williams Laura A | Officer (Chief Patient Officer) | S | ▼ sell | 1,4180 | $6.27 | $8.9K | 429,093 | −0.3% | −<0.01% (now 0.17%) | filing |
| 2026-05-22 | Williams Laura A | Officer (Chief Patient Officer) | S | ▼ sell | 1,9110 | $6.27 | $12.0K | 430,511 | −0.4% | −<0.01% (now 0.17%) | filing |
| 2026-05-22 | Williams Laura A | Officer (Chief Patient Officer) | S | ▼ sell | 2,1570 | $6.27 | $13.5K | 432,422 | −0.5% | −<0.01% (now 0.17%) | filing |
| 2026-05-22 | Williams Laura A | Officer (Chief Patient Officer) | S | ▼ sell | 1,5030 | $6.27 | $9.4K | 434,579 | −0.3% | −<0.01% (now 0.17%) | filing |
| 2026-05-22 | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell | 14,0280 | $6.27 | $87.9K | 1,720,033 | −0.8% | −<0.01% (now 0.69%) | filing |
| 2026-05-22 | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell | 17,9260 | $6.27 | $112.4K | 1,734,061 | −1% | −<0.01% (now 0.70%) | filing |
| 2026-05-22 | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell | 7,8610 | $6.27 | $49.3K | 1,751,987 | −0.4% | −<0.01% (now 0.70%) | filing |
| 2026-05-22 | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell | 14,9330 | $6.27 | $93.6K | 1,759,848 | −0.8% | −<0.01% (now 0.71%) | filing |
| 2026-05-22 | Bishop John E | Officer (See Remarks) | S | ▼ sell | 2,3060 | $6.27 | $14.5K | 336,845 | −0.7% | −<0.01% (now 0.14%) | filing |
| 2026-05-19 | RAAB MICHAEL | Director, Officer (President & CEO) | M | ▼ sell10b5-1 | 20,833→ 20,833 Common Stock | — | — | 332,501 | — | — | filing |
| 2026-05-19 | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell10b5-1 | 41,6660 | $6.28 | $261.6K | 1,774,781 | −2% | −0.02% (now 0.71%) | filing |
| 2026-05-19 | RAAB MICHAEL | Director, Officer (President & CEO) | M | ▲ buy10b5-1 | 20,8330 | $0.99 | $20.6K | 1,816,447 | +1% | +<0.01% (now 0.73%) | filing |
| 2026-04-17 | RAAB MICHAEL | Director, Officer (President & CEO) | M | ▼ sell10b5-1 | 20,834→ 20,834 Common Stock | — | — | 353,334 | — | — | filing |
| 2026-04-17 | RAAB MICHAEL | Director, Officer (President & CEO) | S | ▼ sell10b5-1 | 41,6680 | $6.29 | $262.0K | 1,795,614 | −2% | −0.02% (now 0.72%) | filing |
| 2026-04-17 | RAAB MICHAEL | Director, Officer (President & CEO) | M | ▲ buy10b5-1 | 20,8340 | $0.99 | $20.6K | 1,837,282 | +1% | +<0.01% (now 0.74%) | filing |
Up to 200 most recent filings · select a heading to sort, or open “How to read this” above for definitions · this company on SEC EDGAR.